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Background: Optimal strut coverage and early vascular healing are important factors to reduce the risk of stent
thrombosis. Data on early vascular healing with the new bioresorbable vascular scaffolds (BVS) are lacking.
Further, healing response after BVS implantation in different clinical presentation has not been fully investigated.
Methods and Results: We assessed with optical coherence tomography (OCT) the early vascular response to BVS
implantation in 26 consecutive patients presenting with acute coronary syndrome (ACS) or stable angina (SA).
Images from 16 BVSs (17,166 struts) in ACS patients and 17 BVSs (23,045 struts) in SA patients were analyzed. The
mean implanted BVS diameter and length was 3.1 0.4mm and 20.4 5.8mm. At mean 47.6 6.3 days, overall
99% of BVS struts were covered. There were no differences between ACS and SA on the amount of tissue coverage
per strut (0.09 0.02mm vs. 0.09 0.01mm; P¼ 0.86, respectively) and lumen area stenosis (24.2 19.3% vs.
22.3 22.0%; P¼ 0.78, respectively). However, a numerically higher proportion of protruding (ACS 1.2 2.7%;
SA 4.2 6.5%; P¼ 0.11) and malapposed (ACS 0.4 0.5%; SA 2.4 5.8%; P¼ 0.18) struts were observed in SA
compared to ACS, with trendy better healing score in ACS (1.87 1.67 vs. 5.28 7.28, P¼ 0.08).
Conclusion: Early after BVS implantation almost complete scaffold strut coverage without any thrombi was
observed by OCT, independent by the clinical presentation at index coronary intervention. However, BVS in
ACS lesions were associated with easier strut penetration and a trendy better healing score compared with SA.
(J Interven Cardiol 2017;30:16–23)
Background
Increasing evidence demonstrate similar efﬁcacy of
BVS and newest generation drug-eluting stents (DES)
at 1-year follow-up.1–5 However, registries as well as
randomized trials reported slightly higher rates of
thrombosis in BVS compared with DES.1,2,4,5 Similar
to metallic DES, acute coronary syndrome plays a role
in the risk of scaffold thrombosis, however procedural
aspects such as more demanding size selection with
BVS, incomplete lesion preparation with suboptimal
scaffold expansion, have been identiﬁed to possibly
explain these observations.5,6 The majority of BVS
thrombosis were reported to occur during the ﬁrst
30 days, whichmight suggest, due to thicker polymeric
struts (around 157mm), high ﬂow recirculation around
struts and delayed endothelialization as an additional
substrate for scaffold thrombosis.5,7,8 Although in vivo
data on early BVS vascular healing (within the ﬁrst
2 months) are lacking, similar healing pattern between
BVS and current generation DES was reported at
follow-up later than 6 months after the implanta-
tion.9,10 Nevertheless, intraluminal masses were more

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frequently observed with BVS (12.9% of lesions)
compared with EES (0% of lesions).9 Evidence from
OCT-guided BVS implantation studies suggests that
both BVS expansion and eccentricity are signiﬁcantly
impacted by plaque composition, morphology, and
burden.11 Therefore, in the current study we aimed to
investigate the in vivo early BVS healing response,
assessing the possible impact of clinical presentation at
the index PCI.
Methods
Study Design and Population. We analyzed 26
consecutive patients who underwent OCT examination
6–8 weeks after BVS implantation at the Munich
University Clinic. All these patients presenting with
multivessel disease were scheduled for elective PCI in a
second lesion 6–8 weeks after the index PCI performed
with BVS implantation. OCT examination was part of
the institutional practice after BVS implantation. All
patients’ data were prospectively entered into the
institutional database, based on a predetermined data set.
OCT Imaging and Analysis. OCT was per-
formed by using a frequency domain Lunawave1
system (Terumo1 Medical Corporation, Somerset,
NJ). Intracoronary nitroglycerine (0.2–0.4mg) was
administered before imaging the target vessel with the
implanted BVS. The FastviewTM OCT catheter was
advanced distally to the BVS segment, and imaging
acquisition was obtained during the pullback through a
non-occlusive ﬂushing technique.
Qualitative and quantitative OCT imaging analyses
were performed off-line by two independent readers,
unaware of patient and lesion presentation. An initial
screening of image quality suitable to morphometric
and strut level analysis was performed. Pullbacks were
excluded if more than one third of the total BVS length
was not analyzable. Frames were considered not
analyzable in case>25% of the circumference was not
visible due to blood contamination and or presence of
artifacts.
Quantitativemeasurements at cross-sectional levelwere
performed by using Medis QIvus 3.0 software (Medis,
Medical Imaging Systems, Leiden, The Netherlands),
at 0.25mm longitudinal intervals. The most distal and
proximal section of the scaffold for quantitative
metrics was considered as the ﬁrst frame with at least
50% of the entire circumference encircled by BVS
struts. The peri-scaffold segments, were identiﬁed as
the 5mm proximally and distally located to the
scaffold, analyzed at 1mm intervals and used to
measure the reference lumen. Reference lumen
diameter was calculated as the sum of maximal
diameters measured proximally and distally to the
scaffold divided by two. In case of multiple BVS
implantation, frames with overlapping struts were
excluded from analysis. Quantitative and qualitative
analysis was done according to IWG-IVOCT Consen-
sus document and the recent BVS-OCT standards by
Nakatami et al.12,13 The methodology of quantitative
OCT analysis is shown in Figure 1. Morphometric
analysis was including the lumen area, the scaffold
area, the neointimal area, the % lumen area stenosis
and the thickness of polymeric strut coverage. The
strut level analysis was performed at each single strut
identiﬁed as an optically translucent right angular
black box framed by light-scattering borders. Thick-
ness of strut coverage was deﬁned as distance between
the adluminal surface of the strut and the intersection
of the lumen contour along a straight line between the
long axis of the strut and the center of the stent. Struts
were classiﬁed as malapposed if the abluminal strut
surface was separated from the vessel wall. Struts were
considered uncovered in case of partial or complete
absence of tissue coverage. Protrusion was present if
less than 50% of the strut thickness was impacted by
neointimal tissue (Fig. 2). Healing score was deﬁned
according to Raber and colleagues.14
Quantitative Coronary Angiography Analysis.
Quantitative coronary angiography (QCA) was ana-
lyzed off-line before and after scaffold implantation as
well as at 6–8 weeks follow up with paired matched
angiographic views, using the Medis QAngio XA 7.3
software (Medis, Medical Imaging Systems). The peri-
scaffold segment (5mm proximal and distal to the
scaffold)was used tomeasure the interpolated reference
vessel diameter. The following standard parameters
were computed: reference diameter, minimal lumen
diameter, % diameter stenosis, in scaffold and in peri-
scaffold segment, in stent, and in-segment lumen loss.
Statistical Analysis. The population was divided
in two groups according to clinical presentation at
index PCI. Continuous data are presented as mean
(standard deviation). Categorical data are presented as
counts or proportions (%). Data distribution was tested
for normality using the Kolmogorov–Smirnov test for
goodness of ﬁt. Differences between groups were
checked for signiﬁcance using Student’s t-test or
Wilcoxon rank sum test (continuous data) or the
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chi-square or Fisher’s exact test where the expected
cell value was<5 (categorical variables). A two-tailed
P-value of<0.05 was considered to indicate statistical
signiﬁcance. Statistical software R-Statistics, (version
3.1.0) was used for analysis.
Results
Clinical Baseline Characteristics. A total of 26
patients—12 presenting with ACS and 14 with SA—
who underwent implantation of at least one BVS
(Absorb Version 1.1, Abbott Vascular, Santa Clara,
CA) were considered for this analysis. Mean age of the
overall population was 65 9.8 years, 88.5% of the
patients were men, one third presented with diabetes
mellitus and 92% had multivessel CAD without
signiﬁcant differences between ACS and SA groups
(Table 1).
During index PCI in total 33 BVSs were implanted:
16 in ACS patients and 17 in SA patients. Mean
diameter and length of implanted BVS was
3.1 0.4mm and 20.4 5.8mm, respectively, with-
out differences among ACS and SA patients (Table 1).
Angiographic and OCT Follow Up. Angiographic
follow-upwas performed at 47.6 6.3 days (ACS group
49.7 7.7 days and SA group 45.5 4 .2 days;
P¼ 0.13). No differences regardingQCAmeasurements
were observed between both groups (Table 2).
The analysis of OCT images was done on strut,
cross section and scaffold level. In mean 84.2 22.7
cross sections per scaffold (ACS: 84.1 20.8; SA:
84.4 25.0; P¼ 0.97) and 1643 461 struts per scaffold
(ACS: 1640 386; SA: 1647 536; P¼ 096) were
Figure 1. Quantitative OCT analysis methodology. Panels (A, B, and C) demonstrate the quantitative measurement of the tissue thickness per
strut. The red line depicts the lumen area, the purple line the adluminal surface of the BVS struts; the green line (C) is the equivalent of tissue
thickness per strut, measured in two points per strut. Panels (D, E, and F) shows the quantitative assesement of the neointimal area per frame. The
red line depicts the lumen area, the purple line the stent lumen; the green hachured area shows the neointimal area.
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analyzed. OCT analysis results are shown in Table 3. To
highlight, 99% of the BVS struts were covered without
any difference among ACS and SA patients, Figure 3.
Qualitative OCT analysis revealed a numerically
higher amount of malapposed (P¼ 0.1) and protruding
(P¼ 0.06) struts, as well as a greater neointimal healing
score (P¼ 0.08) in the SA patients compared to the ACS
patients (Fig. 3).
Quantitative OCT analysis showed no differences in
terms of tissue coverage per strut and mean neointimal
area per cross section early BVS implantation between
the ACS and SA groups. Percentages of lumen area
stenosis and lumen diameter stenosis were low in both
groups at 6–8 weeks after BVS implantation and did
not differ signiﬁcantly (Table 3).
Discussion
This is the ﬁrst study investigating the early vascular
healing after BVS implantation and the impact of
clinical presentation on it. The main ﬁndings are: (i) at
47 days after BVS implantation vascular healing of the
stented wall was nearly complete; (ii) BVS implanta-
tion in setting of SA and ACS resulted in similar
outcomes regarding amount of neointimal tissue; (iii)
proportion of malapposed and protruding scaffold
struts was, however, numerically lower after BVS
implantation in the setting of ACS.
Bioresorbable scaffold technology was rapidly
embraced by interventional community due to its
potential of temporary mechanical support of the
treated vessel and the prospective of vascular wall
healing. The recently published randomized trials
demonstrated comparable efﬁcacy and safety of the
Absorb BVS with the standard-bearer EES in
relatively selected patient and lesion subsets.1,3,4,8
However, an increase of scaffold thrombosis was
observed particularly in registry and randomized
studies enrolling a broader spectrum of patients and
lesions4,5,15,16 Inaccurate lesion preparation, inade-
quate BVS size selection or treatments of calciﬁed
lesions have been already identiﬁed to explain this
observation.5,17–19 On the other hand, the fact that
about 70% of scaffold thrombosis occur during the ﬁrst
30 days, might suggest delayed endothelialization of
Figure 2. Qualitative OCT analysis methodology. (A) Covered scaffold struts; (B) uncovered struts, no neointimal tissue was observable apon
the adluminal surface; (C) protruding struts which extend into the vessel lumen, less than 50% of the strut is embedded in neointimal tissue;
(D) Malapposed strut, the abluminal surface of the scaffold strut is not apposed to the vessel wall.
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BVS thick struts (157mm) as an additional substrate
for scaffold thrombosis.5 Against this background, our
ﬁndings are of great clinical relevance. Less than 1% of
scaffold struts were uncovered in our study, despite
the fact that the OCT examination was performed in
about 7 weeks after BVS implantation. There are few
publications reporting the early healing pattern after
implantation of metallic scaffolds.20 At the OCT
studies performed between 1 and 3 months after
stenting, the reported % of uncovered stent struts was
0.1–10% with bare metal stents, 8.6–15% with
sirolimus-eluting stents, 0.1–15% with zotarolimus-
eluting stents, 4.7–23% with EES and 14% with
biolimus-eluting stents.20 Furthermore, the observed
mean tissue (neointima) thickness of 0.09 0.02mm
in our study is comparable to the one reported 1–3
months after implantation of sirolimus- (0.03–
0.04mm), zotarolimus- (0.07–0.08mm), everolimus-
(0.05–0.07mm), biolimus-eluting stents (0.03mm),
while thinner than after bare metal stent implantation
(0.35mm).21–23 Thus, our data showing nearly
complete scaffold coverage at the early phase after
BVS implantation, makes lack of strut endothelializa-
tion as underlying mechanism for scaffold thrombosis,
unlikely.
At follow-ups later than 6months after implantation,
there is evidence about comparable healing patterns
between BVS and DES.9,10 In the randomized TROFI
II study, at 6-month OCT examination, no differences
regarding mean neointimal thickness and % of
uncovered struts was observed between both platforms
in STEMI patients (BVS 0.11 0.03mm and 0.5%;
EES 0.09 0.03mm and 0.6%).10 Gomez-Lara and
colleagues reported similar observation after treatment
Table 1. Clinical and Procedural Baseline Characteristics
All (n¼ 26) ACS (n¼ 12) SA (n¼ 14) P-Value
Age, yrs 65 9.8 63.6 9.6 67 9.9 0.38
Male 23 (88.5) 12 (100.0) 11 (78.6) 0.28
Hypertension 23 (88.5) 10 (83.3) 13 (92.9) 0.89
Hyperlipidemia 7 (26.9) 4 (33.3) 3 (21.4) 0.51
Diabetes 8 (30.8) 5 (41.7) 3 (21.4) 0.49
Smoker 7 (26.9) 4 (33.3) 3 (21.4) 0.75
NYHA class 2 5 (19.2) 2 (16.7) 3 (21.4) >0.99
Chronic kidney disease 4 (15.4) 0 (0.0) 4 (28.6) 0.14
History of MI 7 (26.9) 4 (33.3) 3 (21.4) 0.81
History of PCI 9 (34.6) 4 (33.3) 5 (35.7) >0.99
History of CABG 9 (34.6) 4 (33.3) 5 (35.7) >0.99
LVEF <50% 9 (34.6) 5 (41.7) 4 (28.69 0.85
Extension of CAD 0.07
Single vessel 2 (7.7) 0 (0.0) 2 (14.3)
Two vessel 11 (42.3) 8 (66.7) 3 (21.4)
Three vessel 13 (50.0) 4 (33.3) 9 (64.3)
TIMI flow <3 before PCI 9 (34.6) 7 (58.3) 2 (14.3) 0.05
TIMI flow <3 after PCI 1 (3.8) 0 (0.0) 1 (7.1) >0.99
AHA/ACC class 0.82
A 1 (3.8) 0 (0.0) 1 (7.1)
B1 8 (30.8) 4 (33.3) 4 (28.6)
B2 11 (42.3) 6 (50.0) 5 (35.7)
C 6 (23.1) 2 (16.7) 6 (28.6)
Implanted BVS size (mm) 3.1 0.4 3.2 0.4 3.1 0.4 0.76
Implanted BVS length (mm) 20.4 5.8 20 6 20.8 5.8 0.69
Values aremeanSDor n (%). AMI, acutemyocardial infarction; BVS, bioresorbable vascular scaffold; PCI, percutaneous coronary intervention;
CABG, coronary artery bypass graft; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; TIMI, Thrombolysis In
Myocardial Infarction; CAD, coronary artery disease; AHA, American Heart Association; ACC, Amercican College of Cardiology.
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of patients presenting with stable or clinical unstable
angina—at 1-year OCT examination mean neointimal
thickness was 0.14 0.07mm with BVS versus
0.12 0.05mm with EES, P¼ 0.82, while % uncov-
ered struts was 4.5% with BVS and 5.3% with ESS.9
Differences in values observed between these two
studies might derive from variety of measurement
methodology used, from different time points of OCT
examination but they might also suggest a diverse
healing pattern of BVS in ACS and stable lesions. Data
Table 2. Quantitative Coronary Angiography Measurements
All (n¼ 26) ACS (n¼ 12) SA (n¼ 14) P-Value
Vessel size (mm) 2.57  0.4 2.63  0.4 2.51  0.5 0.48
Stenosis length (mm) 23.7  13.9 23.6  15.5 23.8  13.0 0.98
Minimal lumen diameter (mm)
Before PCI 0.87  0.5 0.77  0.6 0.95  0.4 0.38
In-BVS after PCI 2.36  0.4 2.38  0.4 2.33  0.4 0.77
In-segment after PCI 2.21  0.4 2.36  0.5 2.09  0.4 0.14
In-BVS at re-angiogram 2.30  0.4 2.29  0.3 2.31  0.5 0.94
In-segment at re-angiogram 2.17  0.5 2.17  0.5 2.16  0.4 0.96
% diameter stenosis
Before PCI 66.2  17.6 70.9  21.2 62.2  13.5 0.23
In-BVS after PCI 9.7  7.4 9.9  7.1 9.6  7.9 0.92
In-segment after PCI 15.0  11.0 11.1  8.9 18.4  11.8 0.09
In-BVS at re-angiogram 10.2  7.1 10.9  8.4 9.6  6.2 0.67
In-segment at re-angiogram 15.5  13.9 16.6  16.7 14.6  11.6 0.75
Acute lumen gain (mm) 1.49  0.6 1.61  0.7 1.38  0.5 0.34
Lumen loss (mm)
In-BVS 0.23  0.7 0.28  0.8 0.19  0.7 0.76
In-segment 0.19  0.8 0.26  0.8 0.15  0.8 0.34
Values are meanSD or n (%).
Table 3. OCT Analysis at 6–8 Weeks Follow-Up
All (n¼ 26) ACS (n¼ 12) SAP (n¼ 14) P-Value
Healing score 3.6  5.6 1.9  1.7 5.3  7.3 0.08
Minimal lumen diameter (mm) 2.3  0.5 2.3  0.4 2.4  0.5 0.57
Minimal lumen area (mm2) 4.5  1.7 4.3  1.5 4.7  1.9 0.47
Mean lumen area (mm2) 5.8  2.0 5.6  1.9 5.9  2.1 0.6
Minimal scaffold area (mm2) 5.3  1.8 5.1  1.7 5.4  2.0 0.54
Mean scaffold area (mm2) 6.6  0.2 6,8  2,2 6,5  2,0 0.63
Minimal scaffold diameter (mm) 2.5  0.5 2.5  0.4 2.6  0.5 0.62
Mean scaffold diameter (mm) 2.9  0.5 2.8  0.5 2.9  0.5 0.67
Minimal neointimal area (mm2) 0.4  0.1 0.4  0.1 0.4  0.1 0.81
Mean neointimal area (mm2) 0.9  0.2 0.9  0.2 0.9  0.2 0.71
% Lumen diameter stenosis 12.7  10.8 13.1  9.5 12.3  12.2 0.83
% Lumen area stenosis 23.2  19.3 24.2  16.7 22.3  22.0 0.78
Mean tissue thickness/strut (mm) 0.09  0.02 0.09  0.02 0.09  0.01 0.86
Mean tissue thickness/cross-section (mm) 0.18  0.06 0.19  0.06 0.17  0.06 0.24
Values are meanSD or n (%).
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from histopathology and virtual histology intravascu-
lar ultrasound studies have shown that culprit lesions
of ACS patients present more frequently as thin-cup
ﬁbro-atheromas, with greater amounts of necrotic core
and smaller amounts of ﬁbro-fatty plaque compared to
target lesions in SA patients.24,25 Shaw et al. observed
a correlation between the plaque composition and
scaffold expansion and eccentricity immediately after
BVS implantation.11 Particularly in calciﬁc lesions a
lower BVS expansion and greater eccentricity was
observed highlighting the lower radial strength of the
Absorb BVS compared to metallic scaffolds.18
In our study, neither in the amount of strut coverage
nor in the % of uncovered scaffolds was a difference
amongst ACS and SA patients. On the other hand,
numerically higher % of protruding and malapposed
struts was observed in SA patients compared to ACS
patients, 1.26% versus 4.3% and 0.39% versus 2.48%,
respectively. Although in a recently published study, at
3-month after BVS implantation, reduced neointimal
coverage and a higher proportion of uncovered struts in
ACS patients compared to SAP patients was observed.26
The impact of clinical setting on comparative
performance of BVS and DES has been not investi-
gated and was beyond the aim of our study. Recent
publications suggest however, a greater impact of
procedural aspects on the increased risk of scaffold
thrombosis compared to the clinical presentation at
index PCI.6,27 The observed healing scores in ACS
patients (1.87 1.67) at 47 days after BVS implanta-
tion in our study are comparable with the ones
reported by TROFI-II investigators 6 months after
PCI with BVS (1.74 2.39) and EES (2.80 4.44,
Pnon-inferiority< 0.001) in STEMI patients.10 On the
other hand, in a non-randomized comparison of BVS
and EES healing patterns 1-year after implantation in
patients presenting with stable or unstable angina,
intraluminal masses were observed more frequently
with BVS (in 12.9% of lesions) compared with EES
(0% of lesions), supporting the worse healing score
(5.28 7.28) observed in our SA patients.9 Long-term
presence of strut malapposition, protrusion or coronary
evaginations has been reported after DES or BVS
implantation, and might serve as possible mechanism
for late stent thrombosis due to disturbances of laminar
coronary ﬂow.17,28–30 Our observations suggest an
inferior mechanical performance of BVS in stable
lesions despite similar amount and quality of scaffold
tissue coverage among SA and ACS lesions.
Limitations
Although our study is the ﬁrst report of a early BVS
healing, acute and later in time OCT examinations
were not performed. Furthermore, although there was a
numerical difference in vascular healing parameters
among SA and ACS patients, considering the limited
sample size, the concept of better performance of BVS
in ACS lesions compared to SA lesions remains
hypothesis generating.
Conclusion
Independent of clinical presentation at the index
percutaneous coronary intervention, at mean 47 days
after BVS implantation complete tissue coverage of
struts was observed. BVS treatment of ACS lesions
seems to be associated with a better healing score
compared to SA lesions. However, larger studies are
required to support this hypothesis.
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Figure 3. Results of qualitative OCT strut analysis. Percentages of
uncovered, malapposed and protruding struts 47 days after BRS
implantation in patients with ACS and SAP.
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